Post-earnings recap
Reported
Mon, May 6, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Krystal Biotech's earnings report showed a loss per share that was in line with expectations, but no revenue figures were disclosed. The stock reacted positively, increasing by 0.64%, likely due to management's optimistic outlook on their clinical trials and future data releases. Investors may be encouraged by the focus on advancing their pipeline despite the lack of specific guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management conveyed a cautious optimism regarding their clinical programs. They emphasized the significance of future data that could impact their strategy.
Management expressed confidence in ongoing clinical trials.
They highlighted the importance of upcoming data releases.
Focus remains on advancing their pipeline.